Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review
Open Access
- 21 April 2020
- journal article
- review article
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 8 (4), e17246
- https://doi.org/10.2196/17246
Abstract
Background: Mobile health (mHealth) is a rapidly emerging market, which has been implemented in a variety of different disease areas. Tuberculosis remains one of the most common causes of death from an infectious disease worldwide, and mHealth apps offer an important contribution to the improvement of tuberculosis treatment. In particular, apps facilitating dose individualization, adherence monitoring, or provision of information and education about the disease can be powerful tools to prevent the development of drug-resistant tuberculosis or disease relapse. Objective: The aim of this review was to identify, describe, and categorize mobile and Web-based apps related to tuberculosis that are currently available. Methods: PubMed, Google Play Store, Apple Store, Amazon, and Google were searched between February and July 2019 using a combination of 20 keywords. Apps were included in the analysis if they focused on tuberculosis, and were excluded if they were related to other disease areas or if they were games unrelated to tuberculosis. All apps matching the inclusion criteria were classified into the following five categories: adherence monitoring, individualized dosing, eLearning/information, diagnosis, and others. The included apps were then summarized and described based on publicly available information using 12 characteristics. Results: Fifty-five mHealth apps met the inclusion criteria and were included in this analysis. Of the 55 apps, 8 (15%) were intended to monitor patients' adherence, 6 (11%) were designed for dosage adjustment, 29 (53%) were designed for eLearning/information, 3 (6%) were focused on tuberculosis diagnosis, and 9 (16%) were related to other purposes. Conclusions: The number of mHealth apps related to tuberculosis has increased during the past 3 years. Although some of the discovered apps seem promising, many were found to contain errors or provided harmful or wrong information. Moreover, the majority of mHealth apps currently on the market are focused on making information about tuberculosis available (29/55, 53%). Thus, this review highlights a need for new, high-quality mHealth apps supporting tuberculosis treatment, especially those supporting individualized optimized treatment through model-informed precision dosing and video observed treatment.This publication has 21 references indexed in Scilit:
- Smartphone Applications to Support Tuberculosis Prevention and Treatment: Review and EvaluationJMIR mHealth and uHealth, 2016
- Enhancing management of tuberculosis treatment with video directly observed therapy in New York CityThe International Journal of Tuberculosis and Lung Disease, 2016
- TDMx: A novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routineInternational Journal of Antimicrobial Agents, 2015
- Mobile App Rating Scale: A New Tool for Assessing the Quality of Health Mobile AppsJMIR mHealth and uHealth, 2015
- Serum Drug Concentrations Predictive of Pulmonary Tuberculosis OutcomesThe Journal of Infectious Diseases, 2013
- TB Mobile: a mobile app for anti-tuberculosis molecules with known targetsJournal of Cheminformatics, 2013
- Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer ToolsClinical Pharmacokinetics, 2012
- Mobile Direct Observation Treatment for Tuberculosis Patients: A Technical Feasibility Pilot Using Mobile Phones in Nairobi, KenyaAmerican Journal of Preventive Medicine, 2010
- Forecasting individual pharmacokineticsClinical Pharmacology & Therapeutics, 1979